Trinity Biotech plc (NASDAQ:TRIB) Short Interest Down 50.3% in January

Trinity Biotech plc (NASDAQ:TRIB) was the recipient of a large decrease in short interest in January. As of January 15th, there was short interest totalling 29,100 shares, a decrease of 50.3% from the December 31st total of 58,500 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily volume of 207,300 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC boosted its stake in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent quarter. 78.97% of the stock is currently owned by institutional investors and hedge funds.

Trinity Biotech Stock Performance

Shares of Trinity Biotech stock traded down $0.03 on Friday, reaching $0.90. 439,015 shares of the stock were exchanged, compared to its average volume of 6,336,626. The firm’s 50 day moving average is $0.91 and its 200-day moving average is $1.59. Trinity Biotech has a one year low of $0.74 and a one year high of $3.55. The firm has a market cap of $10.06 million, a PE ratio of -0.40 and a beta of 1.01.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Trinity Biotech in a report on Wednesday. They set a “hold” rating for the company.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.